You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ):2021年度淨利預降29.09%-37.33%
格隆匯 01-25 17:39

格隆匯1月25日丨貝達藥業(300558.SZ)披露2021年度業績預吿,預計2021年度實現歸屬於上市公司股東的淨利潤3.80億元-4.30億元,同比下降29.09%-37.33%;預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤3.51億元-4.01億元,同比增長5.00%-20.00%。

報吿期內,公司營業收入持續保持穩定的增長態勢,凱美納在一代EGFR-TKI市場中穩居領先地位,貝美納市場份額逐漸增加。2021年預計實現營業收入22.00億元-23.00億元,較上年同期增長17.63%-22.98%。

報吿期內,公司經營能力不斷提升,40餘項在研項目持續推進,研發投入較上年同期增加,預計研發投入佔營業收入比例約37.00%-42.00%。公司埃克替尼術後輔助治療適應症、貝伐珠單抗注射液(MIL60)獲得藥品註冊證書,鹽酸恩沙替尼一線治療適應症、伏羅尼布片(CM082片)、甲磺酸貝福替尼膠囊提交藥品註冊申請,BPI-23314、BPI-361175、BPI-21668、MCLA-129、BPI-421286、巴替利單抗、澤弗利單抗、BPI-16350等多個項目獲得臨牀試驗批准。公司全力推進在研項目,爭取早日實現產品價值。

公司2021年限制性股票激勵計劃對報吿期期間費用的影響約6400.00萬元-6600.00萬元。

2020年度,非經常性損益主要系公司出售浙江貝達醫藥科技有限公司股權產生的投資收益,剔除該影響因素,報吿期預計歸屬於上市公司股東的淨利潤同比增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account